Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Endocr Pract. 2012 Nov-Dec;18 Suppl 3:6-26; quiz 27-8. doi: 10.4158/EP12300.RA.

Current issues in GLP-1 receptor agonist therapy for type 2 diabetes.

Author information

  • 1Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, New York, USA. zbloom@gmail.com

Abstract

The clinical management of hyperglycemia in patients with type 2 diabetes mellitus (T2DM) is guided not only by published treatment algorithms, but also by consideration of recent evidence and through consultation with colleagues and experts. Recent studies have dramatically increased the amount of information regarding the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Topics that may be of particular interest to clinicians who treat T2DM patients include relative glycemic control efficacy of GLP-1 RAs, use of GLP-1 RAs across T2DM progression and in combination with insulin, recent data regarding GLP-1 RA safety, nonglycemic actions of GLP-1 RAs, including weight effects, and impact of GLP-1 RAs on patient quality of life and treatment satisfaction. The following review includes expert consideration of these topics with emphasis on recent, relevant reports to illustrate current perspectives.

PMID:
23315305
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for MetaPress.com
    Loading ...
    Write to the Help Desk